Recover Investment Losses: Class Action Initiated Against Regeneron Pharmaceuticals, Inc. (REGN)
Levi & Korsinsky, LLP issued a solicitation announcement regarding a class action lawsuit filed against Regeneron Pharmaceuticals, alleging securities fraud related to its Phase III Fianlimab-Libtayo study. The complaint claims the company disseminated false statements about the trial's statistical assumptions and clinical differentiation, purportedly causing stock declines of 6.2% and 9.8% in late April and mid-May 2026.
Key figures
- Decline apr 29
- 6.2%
- Decline may 18
- 9.8%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.